These mutations include the BCR-ABL fusion event, associated with chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) [29,30], and the BCL2-IGH and IGH-cMyc fusion events, associated with follicular non-Hodgkin lymphoma [31,32]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.